Patents by Inventor Christine Shaw

Christine Shaw has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RSV RNA vaccines
    Patent number: 11911453
    Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The vaccine can be formulated in a lipid nanoparticle.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: February 27, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Andrew J. Bett, Pedro Cejas, Lan Zhang, Christine Shaw
  • RESPIRATORY VIRUS IMMUNIZING COMPOSITIONS
    Publication number: 20230338506
    Abstract: The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: January 29, 2021
    Publication date: October 26, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Christine Shaw, Guillaume Stewart-Jones, Elisabeth Narayanan, Vladimir Presnyak, Sayda Mahgoub Elbashir
  • HMPV MRNA VACCINE COMPOSITION
    Publication number: 20220378904
    Abstract: Provided herein are vaccine composition comprising a chemically-modified messenger ribonucleic acid (mRNA) encoding a hMPV fusion (F) glycoprotein and a chemically-modified mRNA encoding a hPIV3 F glycoprotein formulated in a cationic lipid nanoparticle formulation, and related method for inducing an antigen-specific immune response.
    Type: Application
    Filed: May 5, 2022
    Publication date: December 1, 2022
    Applicant: ModernaTX, Inc.
    Inventors: Lori Panther, Christine Shaw, Igor Smolenov, Michael Watson, Tal Zaks
  • HMPV/hPIV3 mRNA vaccine composition
    Patent number: 11351242
    Abstract: Provided herein are vaccine composition comprising a chemically-modified messenger ribonucleic acid (mRNA) encoding a hMPV fusion (F) glycoprotein and a chemically-modified mRNA encoding a hPIV3 F glycoprotein formulated in a cationic lipid nanoparticle formulation, and related method for inducing an antigen-specific immune response.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: June 7, 2022
    Assignee: ModernaTX, Inc.
    Inventors: Lori Panther, Christine Shaw, Igor Smolenov, Michael Watson, Tal Zaks
  • RSV RNA VACCINES
    Publication number: 20210046173
    Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The vaccine can be formulated in a lipid nanoparticle.
    Type: Application
    Filed: January 28, 2019
    Publication date: February 18, 2021
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Andrew J. Bett, Pedro Cejas, Lan Zhang, Christine Shaw